1. Market Research
  2. > Paladin Labs Inc. – Product Pipeline Review – 2013

Paladin Labs Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 120 pages

Paladin Labs Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Paladin Labs Inc. - Product Pipeline Review - 2013” provides data on the Paladin Labs Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Paladin Labs Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Paladin Labs Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Paladin Labs Inc. - Brief Paladin Labs Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Paladin Labs Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Paladin Labs Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Paladin Labs Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Paladin Labs Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Paladin Labs Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Paladin Labs Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Paladin Labs Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Paladin Labs Inc. and identify potential opportunities in those areas.

Table Of Contents

Paladin Labs Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Paladin Labs Inc. Snapshot 7
Paladin Labs Inc. Overview 7
Key Information 7
Key Facts 7
Paladin Labs Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Paladin Labs Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Paladin Labs Inc. - Pipeline Products Glance 13
Paladin Labs Inc. - Late Stage Pipeline 13
Registration Filed Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Paladin Labs Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Paladin Labs Inc. - Drug Profiles 17
(acetaminophen + tramadol hydrochloride) 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
(estradiol + testosterone) 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
(oxycodone + acetaminophen) 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
fentanyl citrate 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
fomepizole 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
octreotide acetate 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
sumatriptan succinate 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Paladin Labs Inc. - Pipeline Products by Route of Administration 25
Paladin Labs Inc. - Pipeline Products By Mechanism of Action 26
Paladin Labs Inc. - Recent Pipeline Updates 28
Paladin Labs Inc. - Dormant Projects 29
Paladin Labs Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
voclosporin 30
Paladin Labs Inc. - Company Statement 31
Paladin Labs Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Financial Deals Landscape 35
Paladin Labs Inc., Deals Summary 35
Paladin Labs Inc., Pharmaceuticals and Healthcare, Deal Details 38
Asset Transactions 38
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 38
Paladin Labs Acquires OTC Products From Wyeth Pharma 40
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharma 42
Paladin Labs Acquires Miltefosine Rights From AEterna Zentaris 44
Paladin Labs Acquires Zincofax From Johnson and Johnson 46
Paladin Acquires Products From Shire 48
Partnerships 50
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 50
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 52
Paladin Labs Enters Into Distribution Agreement With Common Sense 53
Paladin Labs Enters Into An Distribution Agreement With Protherics 54
Pfizer Amends Co-Marketing Agreement With Paladin Labs 55
Paladin Labs Forms Joint Venture With Isotechnika 56
Paladin Labs Enters Into Agreement With Sylphar 57
Paladin Labs Enters into Distribution Agreement With Mission Pharmacal 58
Paladin Labs Enters Into Distribution Agreement With GlaxoSmithKline 59
Paladin Labs Enters Into Co-Promotion Agreement With Procter and Gamble Pharma 60
Paladin Labs Enters Into Distribution Agreement With KV Pharma 61
Paladin Labs Enters Into Co-Promotion Agreement With Nycomed 62
Paladin Labs Expands Distribution Agreement With Shire HGT 63
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes 64
Licensing Agreements 66
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 66
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 68
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 69
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 71
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan 72
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 74
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 76
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 77
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 79
Isotechnika Pharma Amends Its Licensing Agreement With Paladin Labs For voclosporin 83
Labopharm Enters Into Licensing Agreement With Paladin Labs 84
Paladin Labs Enters Into Licensing Agreement With SpePharm Holding 85
Isotechnika Pharma Enters Into Licensing Agreement With Paladin Labs 86
Paladin Labs Enters Into Licensing Agreement With ProStrakan 88
Paladin Labs Amends Licensing Agreement With Nuvo Research 92
Paladin Labs Enters Into Licensing Agreement With Glide Pharma 93
Labopharm Enters Into A License And Distribution Agreement With Paladin Labs 94
Equity Offering 95
Paladin Labs Completes Private Placement For $40 Million 95
Paladin Labs Completes Public Offering Of $50.9 Million 97
Debt Offering 99
SpePharm Raises $5.42 Million In Private Placement With Paladin 99
Asset Transactions 101
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline From Paladin Labs 101
Paladin Labs Sells T-ACTTM Platform To IMBiotechnologies 103
Acquisition 104
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 104
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 105
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For $60.7 Million 107
Paladin Labs Completes Acquisition Of 44.52% Stake In Litha Healthcare Group For $26.2 Million 109
Paladin Labs Completes Acquisition Of Labopharm 111
Paladin Labs Acquires 35% Stake In Pharmaplan 113
Paladin Labs Acquires Virexx Medical 115
Paladin Labs Acquires BioEnvelop 117
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 120
Disclaimer 120



List of Tables

Paladin Labs Inc., Key Information 7
Paladin Labs Inc., Key Facts 7
Paladin Labs Inc. - Pipeline by Indication, 2013 9
Paladin Labs Inc. - Pipeline by Stage of Development, 2013 10
Paladin Labs Inc. - Monotherapy Products in Pipeline, 2013 11
Paladin Labs Inc. - Combination Treatment Modalities in Pipeline, 2013 12
Paladin Labs Inc. - Filed, 2013 13
Paladin Labs Inc. - Phase III, 2013 14
Paladin Labs Inc. - Phase II, 2013 15
Paladin Labs Inc. - Phase I, 2013 16
Paladin Labs Inc. - Pipeline By Route of Administration, 2013 25
Paladin Labs Inc. - Pipeline Products By Mechanism of Action, 2013 27
Paladin Labs Inc. - Recent Pipeline Updates, 2013 28
Paladin Labs Inc. - Dormant Developmental Projects,2013 29
Paladin Labs Inc. - Discontinued Pipeline Products, 2013 30
Paladin Labs Inc., Subsidiaries 34
Paladin Labs Inc., Deals Summary 35
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 38
Paladin Labs Acquires OTC Products From Wyeth Pharma 40
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharma 42
Paladin Labs Acquires Miltefosine Rights From AEterna Zentaris 44
Paladin Labs Acquires Zincofax From Johnson and Johnson 46
Paladin Acquires Products From Shire 48
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 50
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 52
Paladin Labs Enters Into Distribution Agreement With Common Sense 53
Paladin Labs Enters Into An Distribution Agreement With Protherics 54
Pfizer Amends Co-Marketing Agreement With Paladin Labs 55
Paladin Labs Forms Joint Venture With Isotechnika 56
Paladin Labs Enters Into Agreement With Sylphar 57
Paladin Labs Enters into Distribution Agreement With Mission Pharmacal 58
Paladin Labs Enters Into Distribution Agreement With GlaxoSmithKline 59
Paladin Labs Enters Into Co-Promotion Agreement With Procter and Gamble Pharma 60
Paladin Labs Enters Into Distribution Agreement With KV Pharma 61
Paladin Labs Enters Into Co-Promotion Agreement With Nycomed 62
Paladin Labs Expands Distribution Agreement With Shire HGT 63
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes 64
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 66
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 68
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 69
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 71
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan 72
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 74
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 76
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 77
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 79
Isotechnika Pharma Amends Its Licensing Agreement With Paladin Labs For voclosporin 83
Labopharm Enters Into Licensing Agreement With Paladin Labs 84
Paladin Labs Enters Into Licensing Agreement With SpePharm Holding 85
Isotechnika Pharma Enters Into Licensing Agreement With Paladin Labs 86
Paladin Labs Enters Into Licensing Agreement With ProStrakan 88
Paladin Labs Amends Licensing Agreement With Nuvo Research 92
Paladin Labs Enters Into Licensing Agreement With Glide Pharma 93
Labopharm Enters Into A License And Distribution Agreement With Paladin Labs 94
Paladin Labs Completes Private Placement For $40 Million 95
Paladin Labs Completes Public Offering Of $50.9 Million 97
SpePharm Raises $5.42 Million In Private Placement With Paladin 99
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline From Paladin Labs 101
Paladin Labs Sells T-ACTTM Platform To IMBiotechnologies 103
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 104
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 105
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For $60.7 Million 107
Paladin Labs Completes Acquisition Of 44.52% Stake In Litha Healthcare Group For $26.2 Million 109
Paladin Labs Completes Acquisition Of Labopharm 111
Paladin Labs Acquires 35% Stake In Pharmaplan 113
Paladin Labs Acquires Virexx Medical 115
Paladin Labs Acquires BioEnvelop 117



List of Figures

Paladin Labs Inc. - Pipeline by Indication, 2013 9
Paladin Labs Inc. - Pipeline by Stage of Development, 2013 10
Paladin Labs Inc. - Monotherapy Products in Pipeline, 2013 11
Paladin Labs Inc. - Combination Treatment Modalities in Pipeline, 2013 12
Paladin Labs Inc. - Pipeline By Route of Administration, 2013 25
Paladin Labs Inc. - Pipeline Products By Mechanism of Action, 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.